The additional indications approved by agency for the oral form of Vasolan will provide a wider range of treatment options for patients who are suffering from tachyarrhythmia.
This approval, together with company’s other related products including Tambocor for the indication of tachyarrhythmia and Warfarin as an anticoagulant, will enable Eisai to make further contributions to patients by offering treatment options for managing atrial fibrillation.